CoChat
Sign Up
Cited by 264

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

Peeraphatdit, Thoetchai (Bee), Wang, Jennifer, Odenwald, Matthew A., Hu, Shaomin, Hart, John, Charlton, Michael R.·2020·Hepatology
DOI 10.1002/hep.31227
Open this paper in CoChat — free account

Abstract

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies targeting immune checkpoint molecules. ICIs are an immunotherapy for the treatment of many advanced malignancies. The advent of ICIs has been a major breakthrough in the field of oncology, a fact recognized by the 2018 Nobel Prize in Physiology or Medicine being awarded for the discovery. The Food and Drug Administration approved the first ICI, ipilimumab, in 2011 for the treatment of metastatic melanoma. Seven ICIs are now used in clinical practice, including nivolumab and pembrolizumab for treatment of advanced hepatocellular carcinoma. ICIs are increasingly used across the spectrum of hepatobiliary neoplasia. The utility of ICI therapy has been limited by immune‐related adverse reactions (irAEs) affecting multiple organ systems. Hepatotoxicity is an important irAE, occurring in up to 16% of patients receiving ICIs. Optimizing outcomes in patients receiving ICI therapy requires awareness of and familiarity with diagnosing and management of ICI‐induced immune‐mediated hepatotoxicity (IMH), including approaches to treatment and ICI dose management. The aim of this review article is to (1) provide a comprehensive, evidence‐based review of IMH; (2) perform a systematic review of the management of IMH; and (3) present algorithms for the diagnosis and management of IMH.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.31227

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The incidence of any grade of immune checkpoint inhibitor-related hepatitis in combination therapy is higher than that in monotherapy, for both the combination of two immune checkpoint inhibitors and a combination of an immune checkpoint inhibitor with targeted therapy.

    “The incidence of any grade of ICI-related hepatitis in combination therapy is higher than that in monotherapy, for both the combination of two ICIs and a combination of an ICI with targeted therapy [152].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [152]

  • Immune checkpoint inhibitor-related hepatotoxicity is an indirect form of drug-induced liver injury.

    “However, ICI-related hepatotoxicity is an indirect form of DILI [22,152].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [152]

  • The incidence of any grade of immune checkpoint inhibitor-related hepatitis is usually less than 10% with monotherapy.

    “The incidence of any grade of ICI-related hepatitis is usually < 10% with monotherapy”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [152]

  • The incidence of liver injury induced by cytotoxic T-lymphocyte antigen 4 inhibitors is higher than that induced by programmed cell death 1 inhibitors, particularly at high doses.

    “the incidence of liver injury induced by cytotoxic T-lymphocyte antigen 4 inhibitors is higher than that induced by programmed cell death 1 inhibitors, particularly at high doses.”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [152]

  • The incidence of immune checkpoint inhibitor-related hepatitis depends on the class of drugs, dose, and whether they are used as monotherapy or combination therapy.

    “The incidence of ICI-related hepatitis depends on the class of drugs, dose, and whether they are used as monotherapy or combination therapy [152,153].”

    From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [152]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. 2008, Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways, Immunol Rev, 224, 166, 10.1111/j.1600-065X.2008.00662.x · DOI
  2. 2011, Camouflage and sabotage: tumor escape from the immune system, Cancer Immunol Immunother, 60, 1161, 10.1007/s00262-011-1012-8 · DOI
  3. 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172 · DOI · Paper page
  4. 2016, Molecular and biochemical aspects of the PD‐1 checkpoint, Pathway., 375, 1767
  5. 2018, Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors, J Hepatol, 68, 1181, 10.1016/j.jhep.2018.01.033 · DOI · Paper page
  6. 2009, Drug‐induced liver injury network (DILIN) prospective study: rationale, design and conduct, Drug Saf, 32, 55, 10.2165/00002018-200932010-00005 · DOI · Paper page
  7. 2018, Incidence of grade 3‐4 liver injury under immune checkpoints inhibitors: a retrospective study, J Hepatol, 69, 1396, 10.1016/j.jhep.2018.08.014 · DOI
  8. 2018, Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management, Am J Clin Oncol, 41, 760, 10.1097/COC.0000000000000374 · DOI · Paper page
  9. 2018, Immune‐related hepatitis with immunotherapy: are corticosteroids always needed?, J Hepatol, 69, 548, 10.1016/j.jhep.2018.03.034 · DOI
  10. 2019, Immunotherapy‐related hepatitis: real‐world experience from a tertiary centre, Frontline Gastroenterol, 10, 364, 10.1136/flgastro-2018-101146 · DOI
  11. 2019, Inhibition of immune checkpoints PD‐1, CTLA‐4, and IDO1 coordinately induces immune‐mediated liver injury in mice, PLoS ONE, 14
  12. 2018, Sex and interleukin‐6 are prognostic factors for autoimmune toxicity following treatment with anti‐CTLA4 blockade, J Transl Med, 16, 94, 10.1186/s12967-018-1467-x · DOI · Paper page
  13. 2018, Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune‐related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study, Oncotarget, 9, 15542, 10.18632/oncotarget.24509 · DOI
  14. 2019, Biomarkers for immune checkpoint inhibitor‐mediated tumor response and adverse events, Front Med (Lausanne), 6, 119
  15. 2019, Fulminant hepatitis as an immune‐related adverse event after nivolumab treatment, Pathol Int, 69, 434, 10.1111/pin.12812 · DOI
  16. 2018, Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta‐analysis, JAMA Oncol, 4, 1721, 10.1001/jamaoncol.2018.3923 · DOI · Paper page
  17. 2018, Mortality due to immunotherapy related hepatitis, J Hepatol, 69, 976, 10.1016/j.jhep.2018.06.012 · DOI
  18. 2018, Hepatotoxicity of immune checkpoint inhibitors: an evolving picture of risk associated with a vital class of immunotherapy agents, Liver Int, 38, 976, 10.1111/liv.13746 · DOI · Paper page
  19. 2017, Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors, Clin Radiol, 72, 521, 10.1016/j.crad.2017.04.003 · DOI
  20. 2015, RUCAM in drug and herb induced liver injury: the update, Int J Mol Sci, 17, 14, 10.3390/ijms17010014 · DOI · Paper page
  21. 2019, Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy, Aliment Pharmacol Ther, 50, 800, 10.1111/apt.15413 · DOI
  22. 2018, Immune checkpoint inhibitor–related myositis and myocarditis in patients with cancer, Neurology, 91, e985
  23. 2012, Pathologic changes in ipilimumab‐related hepatitis in patients with metastatic melanoma, Dig Dis Sci, 57, 2233, 10.1007/s10620-012-2140-5 · DOI
  24. 2017, Fibrin ring granulomas in checkpoint inhibitor‐induced hepatitis, Am J Surg Pathol, 41, 134, 10.1097/PAS.0000000000000759 · DOI
  25. 2014, New‐onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment, Oncol Res Treat, 37, 351, 10.1159/000362614 · DOI
  26. 2014, Late development of splenic sarcoidosis‐like lesions in a patient with metastatic melanoma and long‐lasting clinical response to ipilimumab, Oncoimmunology, 3
  27. 2012, Pulmonary sarcoid‐like granulomatosis induced by ipilimumab, J Clin Oncol, 30, e156, 10.1200/JCO.2011.39.3298 · DOI
  28. 2015, Ipilimumab‐associated hepatitis: clinicopathologic characterization in a series of 11 cases, Am J Surg Pathol, 39, 1075, 10.1097/PAS.0000000000000453 · DOI
  29. 2018, Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug‐induced liver injury, Mod Pathol, 31, 965, 10.1038/s41379-018-0013-y · DOI · Paper page
  30. 2016, Pathological characterization of nivolumab‐related liver injury in a patient with glioblastoma, Immunotherapy, 8, 1363, 10.2217/imt-2016-0057 · DOI
  31. 2017, Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group, J Immunother Cancer, 5, 95, 10.1186/s40425-017-0300-z · DOI · Paper page
  32. 2018, Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline, J Clin Oncol, 36, 1714, 10.1200/JCO.2017.77.6385 · DOI · Paper page
  33. 2019, Management of immunotherapy‐related toxicities, version 1.2019, J Natl Compr Canc Netw, 17, 255, 10.6004/jnccn.2019.0013 · DOI · Paper page
  34. 2015, Ipilimumab‐induced toxicities and the gastroenterologist, J Gastroenterol Hepatol, 30, 657, 10.1111/jgh.12888 · DOI
  35. 2011, Resolution of severe ipilimumab‐induced hepatitis after antithymocyte globulin therapy, J Clin Oncol, 29, e237, 10.1200/JCO.2010.32.2206 · DOI
  36. 2015, Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy, BMJ Case Rep
  37. 2017, Nivolumab‐induced cholangitic liver disease: a novel form of serious liver injury, Ann Oncol, 28, 671, 10.1093/annonc/mdw649 · DOI
  38. 2017, Azathioprine combination therapy for steroid‐refractory hepatic immune system‐related adverse events, Eur J Dermatol, 27, 301, 10.1684/ejd.2017.2973 · DOI
  39. 2017, Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti‐thymocyte immunoglobulins, Eur J Cancer, 81, 203, 10.1016/j.ejca.2017.05.018 · DOI
  40. 2017, Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab, Jpn J Clin Oncol, 47, 175, 10.1093/jjco/hyw167 · DOI
  41. 2017, Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer: a case report, Medicine (Baltimore), 96
  42. 2017, Ipilimumab‐associated cholestatic hepatitis: a case report and literature review, Melanoma Res, 27, 380, 10.1097/CMR.0000000000000366 · DOI · Paper page
  43. 2018, Nivolumab induces sustained liver injury in a patient with malignant melanoma, Intern Med, 57, 1789, 10.2169/internalmedicine.9851-17 · DOI
  44. 2018, Anti‐PD‐1‐induced high‐grade hepatitis associated with corticosteroid‐resistant T cells: a case report, Cancer Immunol Immunother, 67, 563, 10.1007/s00262-017-2107-7 · DOI
  45. 2019, Hepatic injury induced by a single dose of nivolumab—a case report and literature review, Klin Onkol, 32, 133
  46. 2019, Evaluation of readministration of immune checkpoint inhibitors after immune‐related adverse events in patients with cancer, JAMA Oncol, 5, 1310‐1317
  47. 2017, Managing immune checkpoint‐inhibitor‐induced severe autoimmune‐like hepatitis by liver‐directed topical steroids, J Hepatol, 66, 657, 10.1016/j.jhep.2016.11.015 · DOI
  48. 2016, The spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma, Clin Infect Dis, 63, 1490, 10.1093/cid/ciw539 · DOI
  49. 2010, Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis, Gastroenterology, 139, 1198, 10.1053/j.gastro.2010.06.046 · DOI
  50. 2015, Immune‐related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center, J Clin Oncol, 33, 3193, 10.1200/JCO.2015.60.8448 · DOI · Paper page
  51. 2019, Infliximab for the treatment of refractory immune‐related hepatitis secondary to checkpoint inhibitors: a case report, JHEP Rep, 1, 66, 10.1016/j.jhepr.2019.02.001 · DOI
  52. 2019, Acute liver failure due to immune‐mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies?, J Hepatol, 70, 564, 10.1016/j.jhep.2018.10.020 · DOI
  53. 2016, Pharmacology C. Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy, Transl Clin Pharmacol, 24, 7, 10.12793/tcp.2016.24.1.7 · DOI

Cited by

Sorted by citations

Metadata

Authors
Peeraphatdit, T. (., Wang, J., Odenwald, M. A., Hu, S., Hart, J., & Charlton, M. R.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2020-07
Volume
72
Issue
1
Pages
315-329
ISSN
  • 0270-9139
  • 1527-3350
DOI
10.1002/hep.31227
Cited by
264
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review